Literature DB >> 22069278

Mapping of conformational autoantibody epitopes in ZNT8.

Janet M Wenzlau1, Lisa M Frisch, John C Hutton, Howard W Davidson.   

Abstract

BACKGROUND: Identification of the major humoral epitopes in zinc transporter 8 (ZnT8) will expand the range of biomarkers for human type 1 diabetes and may provide clues to the mechanisms governing disease progression. Our initial studies suggested that most ZnT8-reactive sera recognize conformational epitopes in the final 100aa region of the molecule. Subsequently we identified residue 325 as a major determinant in two epitopes linked to a genetic polymorphism with high minor allele frequency (rs13266634). The goal of the current study was to extend this analysis to identify non-polymorphic epitopes in ZnT8.
METHODS: Although the carboxy-terminal domains of human and mouse ZnT8 are ∼80% identical, the mouse probe is not precipitated by the majority of human type 1 diabetes sera. Thus to identify key residues we systematically 'humanized' the mouse probe at each position that differs and evaluated the probes in radio-immunoassays.
RESULTS: As previously reported, only the alteration of Q>R325 by itself showed any restoration of binding to human sera. However, when clusters of structurally adjacent variant residues were also changed an additional region of antigenicity was revealed that depended on residues R332, E333, K336, and K340. Using a panel of 112 sera from recent onset subjects tested with the hC325Q and m-R325R332E333K336K340 probes, 39.3% of the subjects were ZnT8(Q)A+ , of which 38.6% (17/44) also recognized the mouse probe.
CONCLUSIONS: We conclude that the mR-REKK probe identifies a third major epitope in ZnT8 that may add to the diagnostic utility of measuring autoantibodies to this molecule.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22069278      PMCID: PMC3664522          DOI: 10.1002/dmrr.1266

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  15 in total

1.  Protein structure prediction on the Web: a case study using the Phyre server.

Authors:  Lawrence A Kelley; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 2.  Autoantibody markers for the diagnosis and prediction of type 1 diabetes.

Authors:  Clive H Wasserfall; Mark A Atkinson
Journal:  Autoimmun Rev       Date:  2005-12-29       Impact factor: 9.754

3.  The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes.

Authors:  C Andersson; K Larsson; F Vaziri-Sani; K Lynch; A Carlsson; E Cedervall; B Jönsson; J Neiderud; M Månsson; A Nilsson; A Lernmark; H Elding Larsson; S-A Ivarsson
Journal:  Autoimmunity       Date:  2011-01-19       Impact factor: 2.815

4.  Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.

Authors:  C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

5.  Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk.

Authors:  P Achenbach; V Lampasona; U Landherr; K Koczwara; S Krause; H Grallert; C Winkler; M Pflüger; T Illig; E Bonifacio; A G Ziegler
Journal:  Diabetologia       Date:  2009-07-10       Impact factor: 10.122

6.  Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes.

Authors:  E Kawasaki; M Uga; K Nakamura; G Kuriya; T Satoh; K Fujishima; M Ozaki; N Abiru; H Yamasaki; J M Wenzlau; H W Davidson; J C Hutton; K Eguchi
Journal:  Diabetologia       Date:  2008-10-11       Impact factor: 10.122

7.  Three-dimensional structure of beta-cell-specific zinc transporter, ZnT-8, predicted from the type 2 diabetes-associated gene variant SLC30A8 R325W.

Authors:  Rob Nm Weijers
Journal:  Diabetol Metab Syndr       Date:  2010-06-05       Impact factor: 3.320

8.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.

Authors:  Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

9.  Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4.

Authors:  Vito Lampasona; Antonio Petrone; Claudio Tiberti; Marco Capizzi; Marialuisa Spoletini; Sergio di Pietro; Marco Songini; Sara Bonicchio; Francesco Giorgino; Ezio Bonifacio; Emanuele Bosi; Raffaella Buzzetti
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

10.  A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes.

Authors:  Janet M Wenzlau; Yu Liu; Liping Yu; Ong Moua; Kimberly T Fowler; Sampathkumar Rangasamy; Jay Walters; George S Eisenbarth; Howard W Davidson; John C Hutton
Journal:  Diabetes       Date:  2008-06-30       Impact factor: 9.461

View more
  8 in total

1.  Chromogranin A is a T cell antigen in human type 1 diabetes.

Authors:  Peter A Gottlieb; Thomas Delong; Rocky L Baker; Lisa Fitzgerald-Miller; Rebecca Wagner; Gabrielle Cook; Marian R Rewers; Aaron Michels; Kathryn Haskins
Journal:  J Autoimmun       Date:  2013-11-13       Impact factor: 7.094

2.  Zinc and the aging brain.

Authors:  Johnathan R Nuttall; Patricia I Oteiza
Journal:  Genes Nutr       Date:  2013-12-24       Impact factor: 5.523

Review 3.  Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review.

Authors:  Renecia A Watkins; Carmella Evans-Molina; Janice S Blum; Linda A DiMeglio
Journal:  Transl Res       Date:  2014-03-04       Impact factor: 7.012

Review 4.  Current and Future Clinical Applications of Zinc Transporter-8 in Type 1 Diabetes Mellitus.

Authors:  Bo Yi; Gan Huang; Zhi-Guang Zhou
Journal:  Chin Med J (Engl)       Date:  2015-09-05       Impact factor: 2.628

Review 5.  T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.

Authors:  Adam L Burrack; Tijana Martinov; Brian T Fife
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-05       Impact factor: 5.555

Review 6.  What has zinc transporter 8 autoimmunity taught us about type 1 diabetes?

Authors:  Claire L Williams; Anna E Long
Journal:  Diabetologia       Date:  2019-08-23       Impact factor: 10.122

7.  Changes in Zinc Transporter 8 Autoantibodies Following Type 1 Diabetes Onset: The Type 1 Diabetes Genetics Consortium Autoantibody Workshop.

Authors:  Janet M Wenzlau; Lisa M Frisch; John C Hutton; Pamela R Fain; Howard W Davidson
Journal:  Diabetes Care       Date:  2015-10       Impact factor: 19.112

8.  Zinc transporter 8 (ZnT8) autoantibody epitope specificity and affinity examined with recombinant ZnT8 variant proteins in specific ZnT8R and ZnT8W autoantibody-positive type 1 diabetes patients.

Authors:  H Skärstrand; E Krupinska; T J K Haataja; F Vaziri-Sani; J O Lagerstedt; Å Lernmark
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.